Powody, dla których warto stosować cilostazol Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2021
Słowa kluczowe:
cilostazol, miażdżyca, przewlekłe niedokrwienie kończyn dolnych, chromanie przestankowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Miażdżyca zarostowa tętnic kończyn dolnych w początkowym stadium charakteryzuje się dolegliwościami o charakterze chromania przestankowego ze zmiennym dystansem uzależnionym od stopnia zaawansowania jej zmian. Jako choroba o charakterze postępującym może doprowadzić do zamykania światła tętnic kończyn dolnych i wytworzenia sieci krążenia obocznego w formie naturalnych by-passów omijających niedrożne odcinki tętnic. Jej rozwój przyspieszają: podeszły wiek, płeć męska, nikotynizm, cukrzyca, zaburzenia o charakterze dyslipidemicznym i nadciśnienie tętnicze. Jedną ze skutecznych form leczenia przewlekłego niedokrwienia kończyn dolnych w przebiegu miażdżycy jest farmakoterapia z zastosowaniem cilostazolu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wojtak, A. (2021). Powody, dla których warto stosować cilostazol . Medycyna Faktów , 14(3(52), 281-284. https://doi.org/10.24292/01.MF.0321.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bennett PC, Silverman S, Gill PS et al. Ethnicity and peripheral artery disease. QJM. 2009; 102: 3-16.
2. Ouriel K. Peripheral arterial disease. Lancet. 2001; 348: 1257-64.
3. Kim ES, Wattanakit K, Gornik HL. Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve Clin J Med. 2012; 79(9): 651-61.
4. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18: 1942-7.
5. Yoshitomi Y, Kojima S, Sugi T et al. Antiplatelet treatment with cilostazol after stent implantation. Heart. 1999; 80: 393-6.
6. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc End Surg. 2007; 33(suppl 1): S1-75.
7. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98: 678-86.
8. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-6.
9. Bramer SL, Tata PNV, Mallikaarjun S. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar Res. 1997; 14(suppl): S612.
10. Strandness DE, Dalman R, Panian S et al. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation. 1998; 98(17 suppl 1): 1-12.
11. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation. 1989; 80: 1549-56.
12. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109: 523-30.
13. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992; 20: 900-6.
14. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001; 35: 48-56.
15. Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002; 90: 1314-9.
2. Ouriel K. Peripheral arterial disease. Lancet. 2001; 348: 1257-64.
3. Kim ES, Wattanakit K, Gornik HL. Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve Clin J Med. 2012; 79(9): 651-61.
4. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18: 1942-7.
5. Yoshitomi Y, Kojima S, Sugi T et al. Antiplatelet treatment with cilostazol after stent implantation. Heart. 1999; 80: 393-6.
6. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc End Surg. 2007; 33(suppl 1): S1-75.
7. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98: 678-86.
8. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-6.
9. Bramer SL, Tata PNV, Mallikaarjun S. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar Res. 1997; 14(suppl): S612.
10. Strandness DE, Dalman R, Panian S et al. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation. 1998; 98(17 suppl 1): 1-12.
11. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation. 1989; 80: 1549-56.
12. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109: 523-30.
13. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992; 20: 900-6.
14. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001; 35: 48-56.
15. Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002; 90: 1314-9.